Table 3 Clinical, biochemical and BAT FDG uptake characteristics of patients with elevated catecholamine levels
Age | Gender | Adr | NorAdr | Dop | BAT severity | SUVmax | Beta-blocker | Alpha-blocker |
|---|---|---|---|---|---|---|---|---|
46 | M | 0.32 | 20 | 0.15 | Severe | 19 | No | No |
23 | M | 0.63 | 15 | 1.1 | Severe | 18 | No | No |
50 | F | 0.67 | 8.2 | 0.55 | Severe | 10 | No | Yes |
22 | F | 0.02 | 7.5 | 0.54 | Nil | <2.5 | No | Yes |
30 | M | 0.84 | 6.3 | 0.60 | Mild | 4.8 | No | Yes |
26 | F | 0.22 | 5.2 | N/A | Nil | <2.5 | No | Yes |
50 | F | 0.47 | 4.1 | 0.82 | Nil | <2.5 | Yes | Yes |
74 | M | 3.4 | 3.6 | 0.16 | Nil | <2.5 | Yes | Yes |
32 | F | 0.30 | 3.1 | 1.2 | Mild | 5 | No | No |
68 | F | 0.21 | 2.4 | N/A | Nil | <2.5 | No | No |
21 | M | 0.28 | 2.2 | 0.86 | Nil | <2.5 | No | No |
31 | F | 1.7 | 1.3 | N/A | Nil | <2.5 | No | Yes |